160 related articles for article (PubMed ID: 20855828)
1. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Schmitt A; Gladieff L; Laffont CM; Evrard A; Boyer JC; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Mousseau M; Pinguet F; Floquet A; Billaud EM; Durdux C; Le Guellec C; Mazières J; Lafont T; Ollivier F; Concordet D; Chatelut E
J Clin Oncol; 2010 Oct; 28(30):4568-74. PubMed ID: 20855828
[TBL] [Abstract][Full Text] [Related]
2. Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Flaherty KT; Stevenson JP; Hahn SM; Redlinger M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):217-22. PubMed ID: 12811513
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
[TBL] [Abstract][Full Text] [Related]
6. Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Chen W; Boras B; Sung T; Hu W; Spilker ME; D'Argenio DZ
AAPS J; 2020 Nov; 22(6):143. PubMed ID: 33156437
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Ng EW; Sandler AB; Robinson L; Einhorn LH
Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
[TBL] [Abstract][Full Text] [Related]
11. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin.
Fujiwara K; Yamauchi H; Suzuki S; Ishikawa H; Tanaka Y; Fujiwara M; Kohno I
Cancer Chemother Pharmacol; 2001; 47(1):22-6. PubMed ID: 11221957
[TBL] [Abstract][Full Text] [Related]
12. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
[TBL] [Abstract][Full Text] [Related]
13. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
[TBL] [Abstract][Full Text] [Related]
14. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; de Bono JS; Schellens JHM
Invest New Drugs; 2020 Aug; 38(4):1117-1128. PubMed ID: 31667659
[TBL] [Abstract][Full Text] [Related]
16. Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Gréen H; Hasmats J; Kupershmidt I; Edsgärd D; de Petris L; Lewensohn R; Blackhall F; Vikingsson S; Besse B; Lindgren A; Brandén E; Koyi H; Peterson C; Lundeberg J
Clin Cancer Res; 2016 Jan; 22(2):366-73. PubMed ID: 26378035
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Joshi A; Guo J; Holleran JL; Kiesel B; Taylor S; Christner S; Parise RA; Miller BM; Ivy SP; Chu E; Venkataramanan R; Beumer JH
Cancer Chemother Pharmacol; 2020 Oct; 86(4):535-545. PubMed ID: 32948918
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel.
Gordon AN; Hancock KC; Matthews CM; Stringer CA; Boston J; Nemunaitis J
Am J Clin Oncol; 1999 Dec; 22(6):601-5. PubMed ID: 10597745
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; de Bono JS; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; De Grève J; Schellens JHM
Invest New Drugs; 2020 Aug; 38(4):1096-1107. PubMed ID: 31637669
[TBL] [Abstract][Full Text] [Related]
20. Effect of Obesity on Hematotoxicity Induced by Carboplatin and Paclitaxel Combination Therapy in Patients with Gynecological Cancer.
Ando Y; Hayashi T; Shiouchi H; Tanaka C; Ito K; Nishibe S; Miyata N; Horiba R; Yanagi H; Fujii T; Kawada K; Ikeda Y; Yamada S
Biol Pharm Bull; 2020 Apr; 43(4):669-674. PubMed ID: 32037352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
